NZ630914A - Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation - Google Patents
Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantationInfo
- Publication number
- NZ630914A NZ630914A NZ630914A NZ63091413A NZ630914A NZ 630914 A NZ630914 A NZ 630914A NZ 630914 A NZ630914 A NZ 630914A NZ 63091413 A NZ63091413 A NZ 63091413A NZ 630914 A NZ630914 A NZ 630914A
- Authority
- NZ
- New Zealand
- Prior art keywords
- transplantation
- methods
- seq
- treating diabetes
- pancreatic islets
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 2
- 210000004153 islets of langerhan Anatomy 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 230000001737 promoting effect Effects 0.000 title 1
- 230000004083 survival effect Effects 0.000 title 1
- 238000002054 transplantation Methods 0.000 title 1
- 108091034117 Oligonucleotide Proteins 0.000 abstract 1
- 101700026522 SMAD7 Proteins 0.000 abstract 1
- 102000049873 Smad7 Human genes 0.000 abstract 1
- 239000000074 antisense oligonucleotide Substances 0.000 abstract 1
- 238000012230 antisense oligonucleotides Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261625904P | 2012-04-18 | 2012-04-18 | |
| PCT/US2013/037150 WO2013158868A1 (en) | 2012-04-18 | 2013-04-18 | Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ630914A true NZ630914A (en) | 2017-01-27 |
Family
ID=48326412
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ630914A NZ630914A (en) | 2012-04-18 | 2013-04-18 | Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US10081809B2 (enExample) |
| EP (1) | EP2839004B1 (enExample) |
| JP (2) | JP6348484B2 (enExample) |
| KR (1) | KR20150003824A (enExample) |
| CN (2) | CN104487574B (enExample) |
| AU (1) | AU2013249191B2 (enExample) |
| CA (1) | CA2870547A1 (enExample) |
| DK (1) | DK2839004T3 (enExample) |
| ES (1) | ES2732252T3 (enExample) |
| IN (1) | IN2014DN08158A (enExample) |
| MX (1) | MX370149B (enExample) |
| NZ (1) | NZ630914A (enExample) |
| RU (1) | RU2667960C2 (enExample) |
| WO (1) | WO2013158868A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITRM20030149A1 (it) | 2003-04-02 | 2004-10-03 | Giuliani Spa | Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico |
| ES2627745T3 (es) | 2008-11-13 | 2017-07-31 | Nogra Pharma Limited | Composiciones antisentido, y procedimientos de fabricación y uso de las mismas |
| US9791442B2 (en) | 2011-09-15 | 2017-10-17 | Nogra Pharma Limited | Methods of monitoring responsiveness to anti-SMAD7 therapy |
| CN104487574B (zh) | 2012-04-18 | 2017-07-07 | 诺格尔制药有限公司 | 治疗糖尿病和/或促进胰岛移植后存活的方法 |
| US10006029B2 (en) | 2013-03-15 | 2018-06-26 | Nogra Pharma Limited | Methods of treating colorectal cancer |
| EP2940115B1 (en) * | 2014-04-30 | 2018-10-17 | The Procter and Gamble Company | Cleaning composition |
| RU2016147569A (ru) | 2014-05-09 | 2018-06-13 | Ногра Фарма Лимитед | Способы лечения воспалительного заболевания кишечника |
| US10337004B2 (en) | 2014-10-17 | 2019-07-02 | Nogra Pharma Limited | Methods and compositions for treating a subject with a SMAD7 antisense oligonucleotide |
| ES2718380T3 (es) * | 2015-10-29 | 2019-07-01 | Procter & Gamble | Composición detergente líquida |
| EP3162878A1 (en) * | 2015-10-29 | 2017-05-03 | The Procter and Gamble Company | Liquid detergent composition |
| US11162097B2 (en) | 2016-02-23 | 2021-11-02 | Nogra Pharma Limited | Methods of treating intestinal fibrosis using SMAD7 inhibition |
| CN112840025A (zh) * | 2018-05-08 | 2021-05-25 | 迈阿密大学 | 用于将治疗性核酸递送到组织的材料方法 |
| JP7137696B2 (ja) | 2019-05-14 | 2022-09-14 | プロヴェンション・バイオ・インコーポレイテッド | １型糖尿病を予防するための方法および組成物 |
| KR20230092863A (ko) | 2020-06-11 | 2023-06-26 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| MX2023013851A (es) | 2021-05-24 | 2023-12-08 | Provention Bio Inc | Metodos para el tratamiento de diabetes tipo 1. |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6656475B1 (en) | 1997-08-01 | 2003-12-02 | The Johns Hopkins University School Of Medicine | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
| SI1456380T1 (sl) * | 2001-11-02 | 2012-11-30 | Giuliani Int Ltd | Smad inhibitorji za zdravljenje cns bolezni |
| ITRM20030149A1 (it) | 2003-04-02 | 2004-10-03 | Giuliani Spa | Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico |
| ES2905724T3 (es) | 2003-06-13 | 2022-04-11 | Alnylam Europe Ag | Acido ribonucleico bicatenario con elevada eficacia en un organismo |
| ITRM20030393A1 (it) * | 2003-08-11 | 2005-02-12 | Giuliani Spa | Uso di oligonucleotidi (odn) antisenso per smad7 per il trattamento delle patologie mediate dal fattore di trascrizione nucleare nf-kb. |
| GB0326778D0 (en) * | 2003-11-18 | 2003-12-24 | Imp College Innovations Ltd | Biological materials and uses thereof |
| RU2434942C2 (ru) * | 2004-09-28 | 2011-11-27 | Кварк Фармасьютикалс, Инк. | Олигорибонуклеотиды и способы их применения для лечения острой почечной недостаточности и других заболеваний |
| JP4991547B2 (ja) | 2004-09-28 | 2012-08-01 | クアーク・ファーマスーティカルス、インコーポレイテッド | 脱毛症、急性腎不全および他の疾患の治療のためのオリゴリボヌクレオチドおよびその使用の方法 |
| WO2007039151A1 (en) * | 2005-09-28 | 2007-04-12 | Universität Zürich | Blockers of transforming growth factor beta and its receptors for the treatment of infectious diseases |
| AU2009237577B2 (en) * | 2008-04-18 | 2014-06-05 | Baxter Healthcare Sa | Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes |
| ES2627745T3 (es) | 2008-11-13 | 2017-07-31 | Nogra Pharma Limited | Composiciones antisentido, y procedimientos de fabricación y uso de las mismas |
| US9791442B2 (en) | 2011-09-15 | 2017-10-17 | Nogra Pharma Limited | Methods of monitoring responsiveness to anti-SMAD7 therapy |
| CN104487574B (zh) | 2012-04-18 | 2017-07-07 | 诺格尔制药有限公司 | 治疗糖尿病和/或促进胰岛移植后存活的方法 |
| EP2970419B8 (en) | 2013-03-15 | 2019-12-11 | Nogra Pharma Limited | Methods of treating colorectal cancer |
| US10006029B2 (en) | 2013-03-15 | 2018-06-26 | Nogra Pharma Limited | Methods of treating colorectal cancer |
| RU2016147569A (ru) | 2014-05-09 | 2018-06-13 | Ногра Фарма Лимитед | Способы лечения воспалительного заболевания кишечника |
| EP3213070A2 (en) | 2014-10-17 | 2017-09-06 | Nogra Pharma Limited | Methods for dosing and monitoring smad7 antisense oligonucleotide treatment using biomarker levels |
| US10337004B2 (en) | 2014-10-17 | 2019-07-02 | Nogra Pharma Limited | Methods and compositions for treating a subject with a SMAD7 antisense oligonucleotide |
| WO2017055611A2 (en) | 2015-09-30 | 2017-04-06 | Nogra Pharma Limited | Methods of using smad7 antisense oligonucleotides based on biomarker expression |
| JP2019507755A (ja) | 2016-02-24 | 2019-03-22 | ノグラ ファーマ リミテッド | Ｓｍａｄ７阻害を使用するセリアック病の処置の方法 |
| WO2018122376A1 (en) | 2016-12-30 | 2018-07-05 | Nogra Pharma Limited | Compositions of smad7 antisense oligonucleotide and methods of treating or preventing psoriasis |
-
2013
- 2013-04-18 CN CN201380020520.2A patent/CN104487574B/zh not_active Expired - Fee Related
- 2013-04-18 KR KR1020147032172A patent/KR20150003824A/ko not_active Abandoned
- 2013-04-18 JP JP2015507173A patent/JP6348484B2/ja not_active Expired - Fee Related
- 2013-04-18 DK DK13721452.4T patent/DK2839004T3/da active
- 2013-04-18 MX MX2014012650A patent/MX370149B/es active IP Right Grant
- 2013-04-18 NZ NZ630914A patent/NZ630914A/en not_active IP Right Cessation
- 2013-04-18 AU AU2013249191A patent/AU2013249191B2/en not_active Ceased
- 2013-04-18 US US14/394,999 patent/US10081809B2/en not_active Expired - Fee Related
- 2013-04-18 ES ES13721452T patent/ES2732252T3/es active Active
- 2013-04-18 CA CA2870547A patent/CA2870547A1/en not_active Abandoned
- 2013-04-18 RU RU2014146170A patent/RU2667960C2/ru not_active IP Right Cessation
- 2013-04-18 CN CN201710440085.9A patent/CN107252492A/zh active Pending
- 2013-04-18 EP EP13721452.4A patent/EP2839004B1/en active Active
- 2013-04-18 WO PCT/US2013/037150 patent/WO2013158868A1/en not_active Ceased
- 2013-04-18 IN IN8158DEN2014 patent/IN2014DN08158A/en unknown
-
2018
- 2018-05-31 JP JP2018104372A patent/JP2018131468A/ja active Pending
- 2018-08-10 US US16/100,906 patent/US10443056B2/en not_active Expired - Fee Related
-
2019
- 2019-09-04 US US16/559,974 patent/US20200239884A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US10443056B2 (en) | 2019-10-15 |
| JP2015514778A (ja) | 2015-05-21 |
| CA2870547A1 (en) | 2013-10-24 |
| MX370149B (es) | 2019-12-03 |
| AU2013249191A1 (en) | 2014-10-09 |
| RU2667960C2 (ru) | 2018-09-25 |
| CN107252492A (zh) | 2017-10-17 |
| CN104487574B (zh) | 2017-07-07 |
| US20190136237A1 (en) | 2019-05-09 |
| US10081809B2 (en) | 2018-09-25 |
| EP2839004A1 (en) | 2015-02-25 |
| US20150315573A1 (en) | 2015-11-05 |
| DK2839004T3 (da) | 2019-07-01 |
| AU2013249191B2 (en) | 2019-01-03 |
| HK1207117A1 (en) | 2016-01-22 |
| ES2732252T3 (es) | 2019-11-21 |
| IN2014DN08158A (enExample) | 2015-05-01 |
| US20200239884A1 (en) | 2020-07-30 |
| RU2014146170A (ru) | 2016-06-10 |
| KR20150003824A (ko) | 2015-01-09 |
| MX2014012650A (es) | 2015-04-08 |
| JP2018131468A (ja) | 2018-08-23 |
| EP2839004B1 (en) | 2019-06-12 |
| JP6348484B2 (ja) | 2018-06-27 |
| CN104487574A (zh) | 2015-04-01 |
| WO2013158868A1 (en) | 2013-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ603901A (en) | Vectors and sequences for the treatment of diseases | |
| PH12018500719A1 (en) | Oligonucleotide compositions and methods thereof | |
| EA201490563A1 (ru) | Антисмысловые олигонуклеотиды для лечения врожденного амавроза лебера | |
| MX2011013176A (es) | Motivos de modificación química para inhibidores y miméticos del miarn. | |
| UA117098C2 (uk) | Сполука, що містить модифікований олігонуклеотид | |
| NZ630596A (en) | Methods for treatment of alport syndrome | |
| RU2014146170A (ru) | Способы лечения диабета и/или улучшения выживания панкреатических островков после трансплантации | |
| IN2014DN10390A (enExample) | ||
| NZ631512A (en) | Compositions and methods for modulating apolipoprotein (a) expression | |
| MX2021014206A (es) | Oligonucleotidos gapmer modificados y metodos de uso. | |
| MX2011008383A (es) | Agonistas basados en acido ribonucleico sintetico de receptor 7 tipo toll. | |
| HK1203552A1 (en) | Differentiation of human embryonic stem cells into single hormonal insulin positive cells | |
| TN2015000079A1 (en) | Antisense polynucleotides to induce exon skipping and methods of treating dystrophies | |
| WO2010132389A3 (en) | Methods for treating cancers and diseases associated with 4-1bb (cd137) expression | |
| TR201818825T4 (tr) | Kardi̇yak hi̇pertrofi̇ni̇n tedavi̇si̇ne ve tanisina yöneli̇k lncrnalar | |
| JP2015514778A5 (enExample) | ||
| EP3301112A3 (en) | Molecular targets for the prevention and/or treatment of fibrosis, hypertrophic scars or keloids | |
| MX2013005875A (es) | Inhibidores de microarn que comprenden nucleotidos bloqueados. | |
| PH12013502402A1 (en) | Method for treating non-small cell lung cancer | |
| NZ741841A (en) | Antisense oligonucleotides for use in treating alzheimer’s disease | |
| IN2014DN10899A (enExample) | ||
| MA39990A (fr) | Induction de régénération cardiaque par micro-arn | |
| WO2013067531A3 (en) | Methods of using microrna 195 in providing neuroprotection | |
| MX2017008462A (es) | Metodos para utilizar oligonucleotidos antisentido para smad7. | |
| MX2013003698A (es) | Agente preventivo o terapeutico contra la fibrosis. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 18 APR 2020 BY COMPUTER PACKAGES INC Effective date: 20170818 |
|
| LAPS | Patent lapsed |